5T4 Binding Agents for Targeted Tumor Cell Elimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches targeting the 5T4 antigen for cancer treatment have not been effective, limiting the potential of 5T4 as a target in cancer therapy.
Innovation Solution
Development of 5T4 binding agents, including antibodies and antibody-drug conjugates (ADCs), that specifically bind to the 5T4 antigen, providing compositions and methods for treating, preventing, or alleviating 5T4-mediated diseases such as various cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If binding agents targeting 5T4 are developed for cancer treatment, then therapeutic efficacy against 5T4-mediated diseases is improved, but previous therapeutic approaches have failed to achieve success
Solution Approach 1:
The patent applies parameter changes by modifying the antibody structure through humanization processes, changing the variable regions and CDRs to achieve both specificity for 5T4 and reduced immunogenicity. This structural parameter modification enables therapeutic success where previous approaches failed.
Solution Approach 2:
The patent employs composite materials by creating humanized antibodies that combine human constant regions with modified variable regions and CDRs derived from non-human sources. This composite structure achieves the dual goal of 5T4 specificity and reduced immune response.
2Measurement precision
If binding agents are designed to target 5T4 specifically, then specificity for tumor cells is improved, but achieving therapeutic success has been difficult
Solution Approach 1:
The patent applies local quality by modifying only the specific regions (variable regions and CDRs) of the antibody that are responsible for antigen binding, while maintaining the human constant regions. This localized modification achieves both specificity for 5T4 and reduced immunogenicity, enabling therapeutic success.
Solution Approach 2:
The patent changes the structural parameters of the antibody's variable regions and CDRs to optimize binding specificity for 5T4 while simultaneously modifying immunogenicity parameters to reduce immune response, thereby achieving both specificity and therapeutic efficacy.
Data Source
AI summary
The present disclosure provides 5T4 binding agents (e.g., antibodies, including multispecific antibodies such as bispecific antibodies, and antibody-drug conjugates) and uses thereof.